Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Basal Health vs Spry

Basal Health
Graded #494

Lower grade

vs+9.099999999999994
Spry
Graded #408

Higher grade

The verdict

Spry takes it — 56.8/100 to 47.7/100.

Spry grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Spry is a weight-loss and anti-aging telehealth platform pairing compounded semaglutide ($199/mo) and tirzepatide ($299/mo) with three longevity peptides — BPC-157, NAD+, and sermorelin ($249–$299/mo).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueSpry +9
45
54
Dose & formulationSpry +24
40
64
Clinical oversightSpry +7
48
55
Labs & monitoringSpry +2
50
52
FulfillmentSpry +3
58
61
Contract termsEven
55
55
Basal Health · left barSpry · right bar

The numbers

MetricBasal HealthSpry
WeighScore47.7/10056.8/100
GradeCC
Scorecard rank#494#408
SemaglutideNot disclosed$199/mo (starting dose, compounded)
TirzepatideNot disclosed$299/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Basal Health

Graded #494 · C

Strengths

  • Stated nationwide coverage (50 states + DC)
  • Metabolic-framework positioning rather than single-product
  • Clinician-supervised dosing rather than a fixed protocol
  • Adaptive monitoring approach

Where it loses points

  • No pricing shown publicly — you must complete intake to see cost
  • Compounding pharmacy partner not named
  • GLP-1 molecules not specified (semaglutide vs tirzepatide vs oral)
  • No LegitScript badge visible on the homepage
  • No FDA compounded-medication disclaimer on the pages reviewed
Spry

Graded #408 · C

Strengths

  • Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
  • Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
  • Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
  • No contracts or commitment required
  • LegitScript Certified with a public verification link

Where it loses points

  • Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
  • Intake reviewed by a nurse practitioner, not an MD
  • States served not disclosed publicly
  • Pharmacy partner not named, and 503A vs 503B designation not specified
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard